By Ivan Pentchoukov
The Food and Drug Administration (FDA) asked a federal judge on Nov. 15 to give it until the year 2076 to fully release the documents in its possession tied to the approval of the Pfizer-BioNTech COVID-19 vaccine.
The FDA’s request was made in a filing as part of a Freedom of Information Act (FOIA) lawsuit by a medical transparency group. The government told the court it has 329,000 pages of documents responsive to the FOIA request and proposed releasing 500 pages per month to allow for redactions of exempt material. At that rate, the FDA would fully release the records in question in just under 55 years.
The plaintiff, Public Health and Medical Professionals for Transparency (PHMPT), is a group of doctors and scientists, including Harvey Risch, a professor of epidemiology at the Yale School of Public Health.
The group filed the lawsuit (pdf) after the FDA denied their request to expedite the release of the records. The plaintiff and the defendant, unable to reach an agreement on a disclosure schedule, are seeking a hearing to argue their cases before the judge, who may eventually make a decision in that regard.
“The FDA’s promise of transparency is, to put it mildly, a pile of illusions,” Aaron Siri, whose firm is representing PHMPT in the lawsuit, wrote in a blog post on Nov. 17.
“It took the FDA precisely 108 days from when Pfizer started producing the records for licensure to when the FDA licensed the Pfizer vaccine,” Siri continued. “Taking the FDA at its word, it conducted an intense, robust, thorough, and complete review and analysis of those documents in order to assure that the Pfizer vaccine was safe and effective for licensure. While it can conduct that intense review of Pfizer’s documents in 108 days, it now asks for over 20,000 days to make these documents available to the public.”
The FDA did not respond to a request for comment.
The FDA licensed the Pfizer COVID-19 vaccine under the Comirnaty label on Aug. 23, 2021, less than four months after Pfizer began submitting documents for full approval of the drug. The FDA approval of the license in late August led to an avalanche of vaccine mandates in the private and public sectors.
COVID-19 is the disease caused by the CCP (Chinese Communist Party) virus, commonly known as the novel coronavirus.
One of the companies involved in the trials of the Pfizer vaccine earlier this month said it was investigating alleged problems brought to light by a whistleblower who told the British Medical Journal (BMJ) that the trial was riddled with issues, including the falsification of data.
The whistleblower, Brook Jackson, alerted the FDA and was fired within hours. Jackson was working for Ventavia Research Group, which operated several of the Pfizer trial sites in the fall of 2020
According to BMJ, one of the oldest medical journals in the world, the FDA did not inspect Ventavia’s trial sites, despite being alerted about the issues.
The FDA told The Epoch Times in an email earlier this month that while it can’t comment on the Ventavia matter, it “has full confidence in the data that were used to support the Pfizer-BioNTech COVID-19 vaccine authorization and the Comirnaty approval.”
As of Nov.14, more than 256 million doses of Pfizer’s COVID-19 vaccine have been administered in the United States.
Zachary Stieber contributed to this report.
- Any civil rights lawsuit against Kyle Rittenhouse ‘will fail,’ legal analysts say
- Buyer’s remorse: Five California laws that have come back to bite them
- Dow Jones Drops 900 Points on Opening Bell as New COVID-19 Variant Roils Markets
- Earthquake Magnitude of 6.1 Shakes Burma-India Border Region
- Oil Prices Drop to 2-month Lows as New COVID-19 Variant Puts Markets on Edge
- Vermont Woman Fired, Denied Unemployment for Refusing Vaccine, Becomes Homeless and Flees to Florida on
- Trump Promises ‘Orderly Transition’ After Biden Certified as President-Elect on
- Trump Says Supreme Court ‘Incompetent and Weak’ Over Election Fraud on
- NH’s Voting Machines Are Capable of Redistributing Votes on
- Dominion’s Parent Company Arranges $400 Million Placement 1 Month Before Election: SEC Filing on